89 related articles for article (PubMed ID: 21920572)
1. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
2. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
3. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
[TBL] [Abstract][Full Text] [Related]
4. Detection of antibodies against epidermodysplasia verruciformis-associated canine papillomavirus 3 in sera of dogs from Europe and Africa by enzyme-linked immunosorbent assay.
Lange CE; Tobler K; Favrot C; Müller M; Nöthling JO; Ackermann M
Clin Vaccine Immunol; 2009 Jan; 16(1):66-72. PubMed ID: 19038784
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice.
Olczak P; Wong M; Tsai HL; Wang H; Kirnbauer R; Griffith AJ; Lambert PF; Roden R
Virology; 2022 Oct; 575():63-73. PubMed ID: 36070626
[TBL] [Abstract][Full Text] [Related]
6. Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein.
Vrablikova A; Brezani V; Psikal I; Fraiberk M; Sebela M; Fojtikova M; Kulich P; Hezova R; Masek J
Front Vet Sci; 2023; 10():1116661. PubMed ID: 37056230
[TBL] [Abstract][Full Text] [Related]
7. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
[TBL] [Abstract][Full Text] [Related]
8. Second-generation prophylactic HPV vaccines: successes and challenges.
Tyler M; Tumban E; Chackerian B
Expert Rev Vaccines; 2014 Feb; 13(2):247-55. PubMed ID: 24350614
[TBL] [Abstract][Full Text] [Related]
9. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
Wang JW; Roden RB
Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
[TBL] [Abstract][Full Text] [Related]
10. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
11. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
12. A multimeric L2 vaccine for prevention of animal papillomavirus infections.
Jagu S; Malandro N; Kwak K; Yuan H; Schlegel R; Palmer KE; Huh WK; Campo MS; Roden RB
Virology; 2011 Nov; 420(1):43-50. PubMed ID: 21920572
[TBL] [Abstract][Full Text] [Related]
13. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
15. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
